300 Participants at Biotech Days


More than 300 participants attended the Biotech Days in Gothenburg arranged by SwedenBIO at its annual meeting. Gothenburg is one of the most expansive biotech regions in Scandinavia and hosts a major R&D center for AstraZeneca. During the past 18 months, SwedenBIO has grown rapidly and has today 75 member companies. Discussions are under way to open up a branch for advanced Med-Tech companies following an interest from leading companies like Gambro AB and Elekta AB. Med-Tech companies share many challenges with biotechs, such as the availability to seed and bridge capital, and to keep up excellence in research and demanding regulatory requirements.

“We have expanded our membership base from seven founders to 75 member companies within the last year. We are happy for the strong support from the industry leaders, which has enabled us to establish SwedenBIO as the voice of the biotech industry. The recognition by leading Med-Tech executives is promising, allowing us to have a coherent approach towards our government and other stakeholders as well as giving critical mass,” says Dr. Hans Nyctelius, CEO of SwedenBIO. The organization, whose objective it is to improve the industrial environment for biotech in Sweden, launched an action plan “A National Biotech Agenda for Growth” in February proposing 18 governmental actions to secure Sweden's leading position. “We have very good discussions with our government and we expect to have a National Biotech Committee in place in Q3,” says Nyctelius.
The Biotech Days hosted a seminar “Future Trends in Biotechnology” where panels on current stem cell research were followed by a speech of Dr. Martin Nicklasson, Executive VP Global Drug Development at AstraZeneca, on their outlook for big pharma. He expressed a strong need for bio-techs and big pharma to collaborate more as well as for a pro-active stance of the Swedish government to allow Astra-Zeneca to strengthen its presence in Sweden. The leading academic IP center in Scandinavia, the Center for Intellectual Property Studies at Chalmers University provided the venue for the seminar “Biotech IP Focus '04”. More than 180 international participants discussed the strategic management of intellectual property rights in biotechnology and how to create value from IP in R&D development and business. Keynote speakers included Robert Blackburn, Head of Legal at Chiron Corp., and Peter de Weerd, Global Head of Patents at Novartis Pharma. SwedenBIO will continue to arrange top-level seminars addressing critical business topics. A Swedish-US biotech day is scheduled for September 9, 2004 in Stockholm.

Dr. Hans Nyctelius, CEO SwedenBIO
eMail: info@swedenbio.com



Exton/Helsingborg – A Swedish specialist for improving glucocorticoid replacement therapy has attracted transatlantic attention. DuoCort Pharma AB, based in Helsingborg, was bought by ViroPharma Incorporated, an US-based...



Uppsala/Basel – Swedish life science initiative Uppsala BIO is set to team up with drugmaker Hoffman-La Roche AG. For the next three years, the cluster will become the ninth member – and the first from Europe – of the Swiss...



Uppsala – Backed by strong clinical research, the development of Orexo AB’s drug candidate OX219 for treatment of opioid dependence is gathering momentum. A clinical Phase I study was carried out to decide the commercial...



Petach Tikva/Lund – Active Biotech AB suffered a severe setback in the development of its oral multiple sclerosis drug laquinimod. Together with ally Teva (Israel), the Swedish drugmaker announced that the substance failed in...



Lund - Researchers from Lund University may have found a viable alternative to animal testing. In an article in the open access journal BMC Genomics (August 2011) they demonstrated that the response of laboratory grown human...



Uppsala - After good interim results Oasmia wastes no time and starts the approval process for its ovarian cancer drug Paclical. The interim analysis, based on data from approximately 400 patients, showed the expected efficacy of...



Petach Tikva/Lund - Active Biotech's experimental multiple sclerosis drug laquinimod failed in a phase III-trial. This is a major setback for the Swedish drug maker and its ally Teva Pharmaceutical Industries from Israel. Both...



Huddinge, Sweden - Medivir cashes in on Medivir. For EUR 31m the Swedishspecialty pharma company sold all North American remaining rights forXerese, a drug against cold sores (herpes labialis), to Swedish Meda. InFebruary 2010,...



Uppsala/Tokyo – Orexo AB’s cancer pain treatment Abstral has reached the Canadian drug market. The Swedish drugmaker confirmed yesterday that Paladin Labs Inc have launched marketing of the sublingual formulation of fentanyl in...



Stockholm – Swedish investor Karolinska Development AB outperformed its own expectations in its Initial Public Offering on the Nasdaq OMX Stockholm. The company sold 15.2 million shares at SEK40 during the offering, raising a...

Displaying results 11 to 20 out of 182

< Previous 11-20 Next >

© 2007-2015 BIOCOM



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week


Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...


All Events



BioVaria 2015

Stock list

All quotes


  • THERAMETRICS0.08 CHF14.29%
  • MEDIGENE10.96 EUR4.88%
  • EVOLVA1.58 CHF3.27%


  • BIOTEST71.00 EUR-3.92%
  • SYNGENTA314.40 CHF-3.65%
  • 4SC5.03 EUR-3.27%


  • 4SC5.03 EUR293.0%
  • WILEX4.33 EUR51.4%
  • SARTORIUS151.00 EUR21.2%


  • CYTOS1.01 CHF-29.4%
  • BIOTEST71.00 EUR-26.9%
  • BIOFRONTERA2.30 EUR-11.2%


  • SANTHERA96.45 CHF2329.5%
  • CYTOS1.01 CHF676.9%
  • WILEX4.33 EUR397.7%


  • MOLOGEN4.94 EUR-55.4%
  • BIOFRONTERA2.30 EUR-29.2%
  • BIOTEST71.00 EUR-20.0%

No liability assumed, Date: 03.05.2015

Current issue

All issues